What question did this study set out to answer?

This case report aims to illustrate the occurrence of late-onset immune-mediated toxicities following CAR-T therapy in a patient with DLBCL.

June 28, 2026Annals of HematologyOpen Access

Immune Effector Cell–associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report

View Full Paper

Ask AI

Bookmark

Authors

Case report reveals fatal immune-mediated toxicity in DLBCL, suggesting late-onset CAR-T challenges.

This case report aims to illustrate the occurrence of late-onset immune-mediated toxicities following CAR-T therapy in a patient with DLBCL.
Examined a 71-year-old woman with heavily pretreated DLBCL
Documented the development of IEC-HS six months after CAR-T infusion
Analyzed the implications of CAR-T cell persistence on immune activation
Patient exhibited IEC-HS with a fatal outcome post-CAR-T therapy.
The case highlights significant late-onset toxicities associated with CAR-T treatment.
Suggests sustained dysregulated immune activation as a contributing factor.

Rincón-López et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark